On Nov. 6, 2025, Eli Lilly announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly’s longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines.

In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programs and millions more who pay out-of-pocket.

Unlocking access to these medicines can be game-changing for Americans with obesity – a risk factor driving more than 200 associated diseases, including heart disease, strokes and certain types of cancers.

Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide), available in a multi-dose pen, and for orforglipron, Lilly’s convenient once-daily obesity pill, provided both receive approval from the U.S. Food and Drug Administration (FDA). States will also have the ability to expand access to Zepbound and orforglipron through Medicaid.

As part of the agreement, Lilly is addressing all four of the Administration’s priorities, including launching new medicines with a more balanced pricing approach across developed nations. In return, Lilly will receive three years of tariff relief and will not be subject to future pricing mandates.